Trial Radar IA

Discutiamo ed esploriamo gli studi clinici con Bristol-Myers Squibb come promotore principale o collaboratore.

Mostrando gli studi clinici che corrispondono al luogo: Australia.

Posso aiutarti a capire le condizioni di salute, i trattamenti o a trovare studi clinici vicini.
8 studi clinici
 
Luogo
Australia
×
 
Titolo dello studio
Stato
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis NCT07441408
Non ancora in arruolamento
Uno studio per valutare l'efficacia di pumitamig rispetto a pembrolizumab in partecipanti con carcinoma polmonare non a piccole cellule avanzato non trattato in precedenza e PD-L1 ≥ 50% (ROSETTA Lung-202) NCT07361510
In arruolamento
Uno studio per valutare pumitamig rispetto a durvalumab dopo chemioradioterapia concomitante in partecipanti con carcinoma polmonare non a piccole cellule (NSCLC) di stadio III non operabile (ROSETTA Lung-201) NCT07361497
In arruolamento
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) NCT07293351
In arruolamento
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) NCT07291076
In arruolamento
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism NCT07284745
Non ancora in arruolamento
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer NCT07221357
In arruolamento
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) NCT07221149
In arruolamento